Skip to main content
English homeNews home
Story
33 of 50

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial  Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound  CNBC Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug  The New York Times Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs  Clinical Trials Arena Eli Lilly’s New Pill Might Help Patients Keep Weight Off After Zepbound, Wegovy  Barron's

Latest News